

**Research Toward a Cure March 15, 2014**

<b>Antibodies</b>	<b>ClinicalTrials.gov Identifier(s)</b>	<b>Manufacturer/Sponsor(s)</b>	<b>Phase</b>	<b>Estimated Study Completion Date</b>
3BNC117 (broadly neutralizing monoclonal antibody)	<a href="#">NCT02018510</a> (not yet open for participant recruitment)	The Rockefeller University	Phase 1	January 2016
<b>Anti-PD-L1 antibody (BMS-936559)</b>	<a href="#">NCT02028403</a> (not yet open for participant recruitment)	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	April 2016
Intravenous immunoglobulin in primary HIV infection	No clinicaltrials.gov entry yet. Study name: CHERUB 001	CHERUB (Collaborative HIV Eradication of viral Reservoirs: UK BRC)		
VRC HIVMAB060-00-AB (VRC01) (broadly neutralizing monoclonal antibody)	<a href="#">NCT01950325</a>	NIAID	Phase 1	September 2016
<b>Anti-Fibrotic</b>				
ACE inhibitors	<a href="#">NCT01535235</a>	University of California, San Francisco/amfAR	Phase 4	August 2014
<b>Combinations</b>				
DNA/Ad5 vaccine, ART intensification (EraMune02)	<a href="#">NCT00976404</a> (closed to enrollment)	Vical/GenVec/U.S. National Institutes of Health (NIH) Vaccine Research Center/Objectif Recherche VACCin Sida (ORVACS)	Phase 2	December 2012 (poster presentation at CROI 2014)
SB-728-T, autologous CD4 T cells genetically modified at the CCR5 gene by zinc finger nucleases + cyclophosphamide	<a href="#">NCT01543152</a>	Sangamo BioSciences	Phase 1/2	December 2013
Vacc-4x peptide-based therapeutic vaccine, lenalidomide	<a href="#">NCT01704781</a>	Bionor Immuno AS	Phase 1/2	August 2014
<b>Antiretroviral Therapy in HIV Controllers</b>				
Emtricitabine/rilpivirine/tenofovir	<a href="#">NCT01777997</a>	AIDS Clinical Trials Group/NIAID	Phase 4	May 2017

<b>Gene Therapies</b>	<b>ClinicalTrials.gov Identifier(s)</b>	<b>Manufacturer/Sponsor(s)</b>	<b>Phase</b>	<b>Estimated Study Completion Date</b>
Dual anti-HIV gene transfer construct	<a href="#">NCT01734850</a>	Calimmune	Phase 1/2	June 2015
SB-728-T, autologous CD4 T cells genetically modified at the CCR5 gene by zinc finger nucleases	<a href="#">NCT01252641</a> (closed to enrollment) <a href="#">NCT01044654</a>	Sangamo BioSciences	Phase 1/2 Phase 1	May 2014 September 2012
Redirected MazF-CD4 autologous T cells for HIV gene therapy (MazF-T)	<a href="#">NCT01787994</a>	Takara Bio/University of Pennsylvania	Phase 1	December 2016
<b>Gene Therapies for HIV-Positive People with Cancers</b>				
Busulfan and gene therapy after frontline chemotherapy in patients with AIDS-related non-Hodgkin lymphoma	<a href="#">NCT01961063</a> (not yet open for participant recruitment)	City of Hope Medical Center	Not listed	October 2030
Genetically modified peripheral blood stem cell transplant in treating patients with HIV-associated non-Hodgkin's or Hodgkin's lymphoma	<a href="#">NCT01769911</a> (not yet open for participant recruitment)	Fred Hutchinson Cancer Research Center	Not listed	February 2019
<b>Latency-Reversing Strategies</b>				
vorinostat (SAHA)	<a href="#">NCT01365065</a> (closed to enrollment) <a href="#">NCT01319383</a>	Merck/University of North Carolina at Chapel Hill/NIAID/Bayside Health	Phase 2 Phase 1/2	March 2016 February 2013
disulfiram (Antabuse)	<a href="#">NCT01944371</a>	University of California, San Francisco/Monash University/amfAR	Phase 1/2	August 2014
panobinostat	<a href="#">NCT01680094</a> (closed to enrollment)	University of Aarhus/Massachusetts General Hospital/Monash University/Karolinska Institutet/Novartis/amfAR	Phase 1/2	December 2013
romidepsin	<a href="#">NCT01933594</a> (not yet open for participant recruitment)	NIAID/ACTG/GILEAD	Phase 1/2	January 2015

<b>Stem Cell Transplantation</b>	<b>ClinicalTrials.gov Identifier(s)</b>	<b>Manufacturer/Sponsor(s)</b>	<b>Phase</b>	<b>Estimated Study Completion Date</b>
Allogeneic transplant in individuals with chemotherapy-sensitive hematologic malignancies and coincident HIV infection (BMT CTN 0903)	<a href="#">NCT01410344</a>	National Heart, Lung, and Blood Institute (NHLBI)/National Cancer Institute (NCI)/ Blood and Marrow Transplant Clinical Trials Network	Phase 2	November 2015
Cord blood transplantation using CCR5-Δ32 donor cells for the treatment of HIV and underlying disease (IMPAACT P1107)	No clinicaltrials.gov entry yet. Study name/link: <a href="#">IMPAACT P1107</a>	NIAID/ The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)		
<b>Therapeutic Vaccines</b>				
GTU-multiHIV, LIPO-5 (DNA + lipopeptide therapeutic vaccines)	<a href="#">NCT01492985</a>	French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)	Phase 2	January 2017
VAC-3S therapeutic vaccine	<a href="#">NCT02041247</a>	InnaVirVax	Phase 2	May 2015
AGS-004 (personalized therapeutic vaccine utilizing patient-derived dendritic cells and HIV antigens)	<a href="#">NCT02042248</a> (not yet open for participant recruitment)	University of North Carolina, Chapel Hill/ Argos Therapeutics/NIH	Phase 1/2	January 2016
Tat Oyi vaccine	<a href="#">NCT01793818</a>	Biosantech	Phase 1/2	June 2015
THV01 lentiviral vector-based therapeutic vaccine	<a href="#">NCT02054286</a> (closed to enrollment)	Theravectys S.A.	Phase 1/2	November 2014
ChAdV63.HIVcons, MVA.HIVcons vaccines	<a href="#">NCT01712425</a> (closed to enrollment)	IrsiCaixa/Fundació Lluita contra la SIDA/Hospital Clinic of Barcelona/ HIVACAT/University of Oxford	Phase 1	April 2015
D-GPE DNA vaccine and M-GPE MVA vaccine	<a href="#">NCT01881581</a>	Centers for Disease Control and Prevention, China	Phase 1	August 2014
HIVAX lentiviral vector-based therapeutic vaccine	<a href="#">NCT01428596</a>	GeneCure Biotechnologies	Phase 1	December 2013
MAG-pDNA, rVSV <sub>IN</sub> HIV-1 Gag (HIV-1 multiantigen DNA vaccine, human IL-12 DNA adjuvant, recombinant vesicular stomatitis virus Indiana HIV Gag vaccine)	<a href="#">NCT01859325</a>	NIAID/Profectus Biosciences, Inc.	Phase 1	November 2016

<b>Treatment Intensification</b>	<b>ClinicalTrials.gov Identifier(s)</b>	<b>Manufacturer/Sponsor(s)</b>	<b>Phase</b>	<b>Estimated Study Completion Date</b>
maraviroc	<a href="#">NCT00795444</a>	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal/Pfizer	Phase 2	September 2013
Peg-Interferon-a2b	<a href="#">NCT01935089</a>	University of Pennsylvania/The Wistar Institute	Phase 2	July 2016
alpha interferon intensification	<a href="#">NCT01295515</a>	NIAID	Phase 1/2	January 2016

<b>Observational Studies</b>	<b>ClinicalTrials.gov Identifier(s)</b>	<b>Manufacturer/Sponsor(s)</b>	<b>Phase</b>	<b>Estimated Study Completion Date</b>
Establish and characterize an acute HIV infection cohort in a high risk population	<a href="#">NCT00796146</a>	South East Asia Research Collaboration with Hawaii/Armed Forces Research Institute of Medical Sciences, Thailand/Thai Red Cross AIDS Research Centre	N/A	July 2019
Prospective HIV chemotherapy cohort study (CHERUB 003)	<a href="#">NCT01902693</a>	Imperial College London/CHERUB	N/A	January 2015
Tissue drug levels of HIV medications	<a href="#">NCT01490346</a>	University of Minnesota - Clinical and Translational Science Institute/NIAID	N/A	December 2013
Towards HIV functional cure (ULTRASTOP) - antiretroviral treatment interruption	<a href="#">NCT01876862</a> (not yet open for participant recruitment)	Objectif Recherche Vaccins SIDA/Fondation Bettencourt-Schueller	N/A	December 2015

Completed Studies	ClinicalTrials.gov Identifier(s)	Manufacturer/Sponsor(s)	Phase	Available Results
<b>Combinations</b>				
Antiretroviral intensification +/- interleukin-7	<a href="#">NCT01019551</a>	Objectif Recherche Vaccins SIDA (ORVACS)/Cytheris SA/Merck Sharp & Dohme Corp./Pfizer	Phase 2	CROI 2013, <a href="#">Abstract D-1003</a> (available via NATAP)
MVA-B + disulfiram	Not entered in clinicaltrials.gov	Hospital Clinic of Barcelona/HIVACAT	Phase I	AIDS Vaccine 2013, <a href="#">Poster P04.12</a>
<b>Gene Therapies</b>				
SB-728-T, autologous CD4 T cells genetically modified at the CCR5 gene by zinc finger nucleases	<a href="#">NCT00842634</a>	Sangamo Biosciences/ University of Pennsylvania	Phase 1	CROI 2012, <a href="#">Abstract 155</a> (available via NATAP)
<b>Latency-Reversing Strategies</b>				
disulfiram (Antabuse)	<a href="#">NCT01286259</a>	University of California, San Francisco/Johns Hopkins University/amfAR	Not specified	<a href="#">Clin Infect Dis. (2014) 58 (6): 883-890.</a>
valproic acid	<a href="#">NCT00289952</a> <a href="#">NCT00614458</a> <a href="#">NCT00312546</a>	McGill University/Canadian Foundation for AIDS Research/CIHR Canadian HIV Trials Network University of North Carolina, Chapel Hill/NIAID/Abbott/Merck Sharp & Dohme Corp University of North Carolina, Chapel Hill	Phase 2 Phase 2 Phase 1	<a href="#">HIV Med. 2012 May;13(5):291-6.</a> <a href="#">PLoS ONE 5(2): e9390.</a>
<b>Therapeutic vaccines</b>				
MVA-B	<a href="#">NCT01571466</a>	Hospital Clinic of Barcelona	Phase 1	AIDS Vaccine 2013, <a href="#">Poster P04.37 LB</a>